Invasive BC, which is positive for either one or more of the three important biomarkers ER, PR, and HER2, can be targeted by hormone-based therapy, whereas tumors that are negative for all three receptors, classified as triple-negative breast cancers (TNBC), do not benefit from hormone-based therapy. This evidence concerns the gene PGR and breast cancer.